Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer

Go back to Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer
(NASDAQ: PPCB) Delayed: 0.61 -0.02 (3.17%)
Previous Close $0.63    52 Week High
Open $0.66    52 Week Low
Day High $0.67    P/E N/A 
Day Low $0.60    EPS
Volume 160,446